Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Genocea Biosciences Inc (NASDAQ:GNCA)

5.94
Delayed Data
As of Mar 29
 +0.31 / +5.51%
Today’s Change
3.28
Today|||52-Week Range
8.07
+44.17%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$160.4M

Company Description

Genocea Biosciences, Inc. operates as a clinical stage biotechnology company. The company engages in discovering and developing vaccines to address infectious diseases. It uses its proprietary platform technology, antigen lead acquisition system to discover and develop novel vaccine candidates. The company's pipeline consists of GEN-003, GEN-004, GEN-009, Epstein-Barr virus, patient stratification, next gen HSV, Chlamydia and malaria. Genocea Biosciences was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Contact Information

Genocea Biosciences, Inc.
Cambridge Discovery Park
Cambridge Massachusetts 02140
P:(617) 876-8191
Investor Relations:
(617) 715-7795

Employees

Shareholders

Mutual fund holders32.03%
Individual stakeholders30.60%
Other institutional17.97%

Top Executives

Chip ClarkPresident, Chief Executive Officer & Director
Jonathan Michael PooleChief Financial Officer & Head-Investor Relations
Jessica Baker FlechtnerChief Scientific Officer
Seth V. HetheringtonChief Medical Officer
Eric S. HoffmanChief Business Officer